A case series of nicotine nasal spray in the treatment of tobacco dependence among patients with schizophrenia

Jill Williams, Douglas M. Ziedonis, Jonathan Foulds

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

A retrospective case series of 12 smokers with schizophrenia or schizoaffective disorder who had not successfully quit smoking with previous treatments for tobacco dependence were treated with nicotine nasal spray. All but one patient (92 percent) tolerated the nasal spray well, and nine (75 percent) used it at maximal doses for prolonged periods. After treatment five patients (42 percent) were abstinent from smoking for more than 90 days, and four patients (33 percent) substantially reduced the amount that they smoked. Ten patients (83 percent) used the spray in combination with other medications, and all received psychosocial support. Nicotine nasal spray was found to be well tolerated.

Original languageEnglish (US)
Pages (from-to)1064-1066
Number of pages3
JournalPsychiatric Services
Volume55
Issue number9
DOIs
StatePublished - Sep 1 2004

Fingerprint

Tobacco Use Cessation Products
Tobacco Use Disorder
Schizophrenia
Smoking
Nasal Sprays
Therapeutics
Psychotic Disorders

All Science Journal Classification (ASJC) codes

  • Psychiatry and Mental health

Cite this

@article{c211b833a1704a5aa591de08efba4d73,
title = "A case series of nicotine nasal spray in the treatment of tobacco dependence among patients with schizophrenia",
abstract = "A retrospective case series of 12 smokers with schizophrenia or schizoaffective disorder who had not successfully quit smoking with previous treatments for tobacco dependence were treated with nicotine nasal spray. All but one patient (92 percent) tolerated the nasal spray well, and nine (75 percent) used it at maximal doses for prolonged periods. After treatment five patients (42 percent) were abstinent from smoking for more than 90 days, and four patients (33 percent) substantially reduced the amount that they smoked. Ten patients (83 percent) used the spray in combination with other medications, and all received psychosocial support. Nicotine nasal spray was found to be well tolerated.",
author = "Jill Williams and Ziedonis, {Douglas M.} and Jonathan Foulds",
year = "2004",
month = "9",
day = "1",
doi = "10.1176/appi.ps.55.9.1064",
language = "English (US)",
volume = "55",
pages = "1064--1066",
journal = "Psychiatric Services",
issn = "1075-2730",
publisher = "American Psychiatric Association",
number = "9",

}

A case series of nicotine nasal spray in the treatment of tobacco dependence among patients with schizophrenia. / Williams, Jill; Ziedonis, Douglas M.; Foulds, Jonathan.

In: Psychiatric Services, Vol. 55, No. 9, 01.09.2004, p. 1064-1066.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A case series of nicotine nasal spray in the treatment of tobacco dependence among patients with schizophrenia

AU - Williams, Jill

AU - Ziedonis, Douglas M.

AU - Foulds, Jonathan

PY - 2004/9/1

Y1 - 2004/9/1

N2 - A retrospective case series of 12 smokers with schizophrenia or schizoaffective disorder who had not successfully quit smoking with previous treatments for tobacco dependence were treated with nicotine nasal spray. All but one patient (92 percent) tolerated the nasal spray well, and nine (75 percent) used it at maximal doses for prolonged periods. After treatment five patients (42 percent) were abstinent from smoking for more than 90 days, and four patients (33 percent) substantially reduced the amount that they smoked. Ten patients (83 percent) used the spray in combination with other medications, and all received psychosocial support. Nicotine nasal spray was found to be well tolerated.

AB - A retrospective case series of 12 smokers with schizophrenia or schizoaffective disorder who had not successfully quit smoking with previous treatments for tobacco dependence were treated with nicotine nasal spray. All but one patient (92 percent) tolerated the nasal spray well, and nine (75 percent) used it at maximal doses for prolonged periods. After treatment five patients (42 percent) were abstinent from smoking for more than 90 days, and four patients (33 percent) substantially reduced the amount that they smoked. Ten patients (83 percent) used the spray in combination with other medications, and all received psychosocial support. Nicotine nasal spray was found to be well tolerated.

UR - http://www.scopus.com/inward/record.url?scp=4444366725&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4444366725&partnerID=8YFLogxK

U2 - 10.1176/appi.ps.55.9.1064

DO - 10.1176/appi.ps.55.9.1064

M3 - Article

VL - 55

SP - 1064

EP - 1066

JO - Psychiatric Services

JF - Psychiatric Services

SN - 1075-2730

IS - 9

ER -